On Friday, Shares of International Business Machines Corp. (NYSE:IBM), lost -0.65% to $172.22.
International Business Machines, the University of Melbourne and the University of Queensland have moved a step closer to identifying the nanostructure of cellulose – the basic structural component of plant cell walls.
Tapping into the IBM Blue Gene/Q supercomputer at the Victorian Life Sciences Computation Initiative (VLSCI), researchers have been able to model the structure and dynamics of cellulose at the molecular level. The insights could pave the way for more disease resistant varieties of crops and enhance the sustainability of the pulp, paper and fibre industry – one of the main users of cellulose.
The work, which was described in a recent scientific paper published in Plant Physiology, represents a noteworthy step towards its understanding of cellulose biosynthesis and how plant cell walls assemble and function. The research is part of a longer-term program to develop a 3D computer simulated model of the entire plant wall. Globally, IBM is a leader in the field of computational biology - the interface of information technology and biology through which scientists are exploring ways to improve crop yields, enhance food traceability and secure supply chains.
International Business Machines Corporation provides information technology (IT) products and services worldwide. The company’s Global Technology Services segment provides IT infrastructure and business process services, such as outsourcing, processing, integrated technology, cloud, and technology support.
Shares of Actavis plc (NYSE:ACT), inclined 0.04% to $ 301.35, during its last trading session.
Actavis, declared that Brent Saunders, CEO and President of Actavis, will provide an overview and update of the Company’s business at Bernstein’s Thirty-First Annual Planned Decisions Conference 2015 in New York City.
The presentation will take place on Thursday, May 28, 2015 at 11:00 a.m. Eastern Time at the Waldorf Astoria Hotel, New York, NY.
Actavis plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic, branded generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products.
At the end of Friday’s trade, Shares of Inspire MD Inc (NYSEMKT:NSPR), gained 14.29% to $ 0.24.
Inspire, declared that its Guard Embolic Prevention System stated positive results in PARADIGM, lead by principle investigator Prof. Piotr Musialek, at the EuroPCR conference on May 22, 2015 in Paris, France.
PARADIGM, an investigator-initiated Prospective evaluation of All-comer peRcutaneous cArotiD revascularization In symptomatic and raised-risk asymptomatic carotid artery stenosis, using CGuard™ Mesh-covered embolic prevention stent system, indicated that the CGuard™ system is appropriate for use in an all-comer carotid revascularization population and is associated with an extremely favorable angiographic and clinical outcome.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex coronary and vascular diseases.
Finally, Aetna Inc(NYSE:AET), ended its last trade with -0.15% loss, and closed at $ 114.52.
Aetna, declared a quarterly cash dividend of $0.25 per share on the company’s common stock. The dividend is payable on July 31, 2015, to shareholders of record at the close of business on July 16, 2015.
Declaration and payment of future dividends is at the discretion of the Board and may be adjusted as business needs or market conditions change.
Aetna Inc. operates as a health care benefits company in the United States. It operates through three segments: Health Care, Group Insurance, and Large Case Pensions. The Health Care segment offers medical, pharmacy benefit administration services, dental, behavioral health, and vision plans on an insured basis, and an employer-funded or administrative basis.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
